Dosing & Uses
Dosage Forms & Strengths
liquid
- 100%
Constipation
15-45 mL/day PO, single or divided doses
Kondremul: 30-75 mL/day
Dosing considerations
Take only at bedtime
Do not take with meals
May take as single dose or divided dose
Dosage Forms & Strengths
liquid
- 100%
Constipation
<6 years
- 15-30 mL/year of age; not to exceed 240 mL/day
6-12 years
- 5-15 mL/day divided qDay, single or divided doses
- Kondremul: 10-25 mL/day
>12 years
- 15-45 mL/day PO, single or divided doses
- Kondremul: 30-75 mL/day
Dosing considerations
Take only at bedtime
Do not take with meals
May take as single dose or divided dose
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (4)
- beta carotene
mineral oil decreases levels of beta carotene by drug binding in GI tract. Use Caution/Monitor.
- digoxin
mineral oil decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
- levonorgestrel oral/ethinylestradiol/ferrous bisglycinate
mineral oil decreases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely.
- vitamin D
mineral oil will decrease the level or effect of vitamin D by Other (see comment). Use Caution/Monitor. Avoid concomitant use of mineral oil and vitamin D supplements to avoid risk of decreased absorption of vitamin D. Applies to only oral administration of these agents.
Minor (21)
- antithrombin alfa
mineral oil decreases levels of antithrombin alfa by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- antithrombin III
mineral oil decreases levels of antithrombin III by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- argatroban
mineral oil decreases levels of argatroban by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- bemiparin
mineral oil decreases levels of bemiparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- bivalirudin
mineral oil decreases levels of bivalirudin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- dabigatran
mineral oil decreases levels of dabigatran by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- dalteparin
mineral oil decreases levels of dalteparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- docusate
docusate increases levels of mineral oil by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- enoxaparin
mineral oil decreases levels of enoxaparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ethinylestradiol
mineral oil decreases levels of ethinylestradiol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- fondaparinux
mineral oil decreases levels of fondaparinux by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- heparin
mineral oil decreases levels of heparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- mestranol
mineral oil decreases levels of mestranol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- phenindione
mineral oil decreases levels of phenindione by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- protamine
mineral oil decreases levels of protamine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- sulfadiazine
mineral oil decreases levels of sulfadiazine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- sulfamethoxazole
mineral oil decreases levels of sulfamethoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- sulfisoxazole
mineral oil decreases levels of sulfisoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- vitamin A
mineral oil decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- vitamin E
mineral oil decreases levels of vitamin E by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- vitamin K1 (phytonadione)
mineral oil decreases levels of vitamin K1 (phytonadione) by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Lipid pneumonitis if reclined
Incontinence of feces
Intestinal malabsorption
Impaired absorption of fat-soluble vitamins
Rectal discharge
Anal pruritus and irritation
Abdominal cramps
Nausea
Vomiting
Lipid pneumonitis with aspiration
Warnings
Contraindications
Fecal impaction, intestinal obstruction or perforation, colostomy, ileostomy, ulcerative colitis, diverticulitis
Bedridden patient
Pregnancy
<6 years
Use >1 week
Patients with esophageal or gastric retention, dysphagia, or hiatal hernia
Cautions
Conditions that interfere with swallowing or epiglottal function may increase risk of aspiration, which can result in lipid pneumonitis
Aspiration risk increases in the elderly
If taking other drugs, take this product 2 or more hours before or after other drugs
If experience bleeding after use or fail to have bowel movement after use, discontinue use and talk to healthcare professional
Pregnancy & Lactation
Pregnancy
Ask healthcare professional
Lactation
Not known if excreted in breast milk; ask a healthcare professional
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Emollient; retards colonic absorption of water; decreases water absorption and lubricates intestine, which eases passage of stool
Pharmacokinetics
Onset of action: 6-8 hr (PO)
Distribution: Colon
Excretion: Feces
Absorption: minimal
